

Oncology Today with Dr Neil Love: CAR T-Cell Therapy in Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following CD19-directed chimeric antigen receptor (CAR) T-cell therapies is approved for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma or transformed lymphoma?
 - a. Tisagenlecleucel
 - b. Axicabtagene ciloleucel
 - c. Lisocabtagene maraleucel
 - d. Both a and b
 - e. Both b and c
 - f. Both a and c
 - g. All of a, b and c

2. Which of the following CAR T-cell therapies is approved for patients with R/R mantle cell lymphoma?
 - a. Axicabtagene ciloleucel
 - b. Brexucabtagene autoleucel
 - c. Tisagenlecleucel
 - d. Both a and b
 - e. Both b and c
 - f. Both a and c
 - g. All of a, b and c

3. Which of the following agents is associated with the lowest rate of Grade ≥ 3 cytokine release syndrome (CRS)?
 - a. Axicabtagene ciloleucel
 - b. Brexucabtagene autoleucel
 - c. Lisocabtagene maraleucel

4. Which of the following agents is effective in the management of CRS in patients receiving CAR T-cell therapy?
 - a. Tocilizumab
 - b. Romiplostim
 - c. Tafasitamab
 - d. Daratumumab